Skip to main content

Table 1 Demographic and clinical characteristics of cohorts 1 and 2. GR and NR indicate EULAR good responders and non-responders respectively. Numbers in brackets after each attribute represent percentages or standard deviation (SD) of that attribute, as indicated

From: Molecular profiling of rheumatoid arthritis patients reveals an association between innate and adaptive cell populations and response to anti-tumor necrosis factor

  Cohort 1 Cohort 2
  GR NR p GR NR p
N 19 21 N/A 21 15 N/A
Female, N (%) 15 (79) 19 (90) 0.56 16 (76) 12 (80) 1
Age§, mean (SD) 54 (13) 56 (13) 0.48 55 (12) 51 (9.9) 0.41
White, N (%) 17 (89) 14 (67) 0.18 19 (90) 13 (87) 1
BMI§, mean (SD) 29 (7.6) 30 (6.3) 0.45 30 (7) 33 (7.1) 0.092
College educated§, N (%) 10 (53) 13 (62) 0.79 12 (57) 10 (67) 0.82
Non-smoker§, N (%) 8 (42) 14 (67) 0.21 14 (67) 9 (60) 0.95
Current or previous smoker§, N (%) 11 (58) 7 (33) 0.21 7 (33) 6 (40) 0.95
Infliximab, N (%) 8 (42) 9 (43) 1 6 (29) 8 (53) 0.25
Adalimumab, N (%) 11 (58) 12 (57) 1 15 (71) 7 (47) 0.25
SJC28 [BL]§, mean (SD) 6.7 (3.7) 9.1 (5.5) 0.18 9.6 (5.5) 8.7 (4.9) 0.75
TJC28 [BL], mean (SD)* 9 (6.2) 15 (8.3) 0.027 11 (6.7) 14 (5.7) 0.16
ln (CRP) [BL]§, mean (SD) 1.6 (1.6) 1.2 (1.8) 0.53 1.5 (1.4) 1.8 (1.1) 0.43
DAS28-CRP [BL], mean (SD)* 4.5 (0.78) 5.2 (0.94) 0.016 4.8 (0.83) 5.2 (0.66) 0.054
RA duration§, mean (SD)* 5.4 (7.5) 1.9 (1.7) 0.023 5 (6.5) 7.2 (8.3) 0.5
RF+, N (%) 16 (84) 12 (57) 0.13 16 (76) 8 (53) 0.28
CCP+, N (%)* 16 (84) 8 (38) 0.0081 17 (81) 6 (40) 0.03
  1. *Difference between good and non-responders at baseline for this attribute is statistically significant (p < 0.05) in at least one of the cohorts
  2. §Propensity score informing selection of the patients was based on age, level of education, smoking history, BMI, duration of disease, and baseline CRP and SJC28